昭衍新藥(603127.SH)放棄昭衍生物5%股份優先受讓權
格隆匯10月18日丨昭衍新藥(603127.SH)公佈,北京昭衍生物技術有限公司(下稱“昭衍生物”)為公司和關聯方共青城子衿投資中心(有限合夥)(下稱“子衿投資”)共同投資的公司,昭衍生物註冊資本為5億元(人民幣,下同),其中子衿投資為4.5億元、持股90%(子衿投資受讓了關聯方熠昭(北京)醫藥科技有限公司所持昭衍生物90%股權),公司投資為0.5億元、持股10%。
昭衍生物根據運營發展需要,擬引進戰略股東Blacc Management Limited,以促進自身發展。為此,子衿投資擬將持有的昭衍生物尚未實繳出資的5%股份轉讓給Blacc Management Limited,轉讓價格為24萬元。
昭衍新藥根據自身發展需要,經綜合考慮,擬決定放棄行使子衿投資本次股權轉讓的優先受讓權,放棄優先受讓權不會改變公司對昭衍生物的持股比例。昭衍生物本次股權轉讓完成後,股東變更為子衿投資、昭衍新藥、Blacc Management Limited,持股比例分別為85%、10%、5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.